Clinical trials: Subcutaneous Injection
Skin Aging
Effectiveness and Safety of Cellbooster Shape in Healthy Subjects
SUISSELLE has developed a CE marketed (2021) HA-based superficial epidermis/dermis injection filler and skinbooster product, Cellbooster® Shape (CBS). CBS is produced using patented CHAC Technology.
- Trial name
- NCT07636512
- Testing
- Skin booster injection (CBS)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Suisselle
Pain, Acute Pain
Pain Induced by m-Cresol as Preservative
Preservatives such as m-Cresol are essential components in many subcutaneously injected medications, including insulin or human growth hormone, to prevent bacterial growth.
- Conditions
- Pain, Acute Pain, Healthy Volunteer Study
- Trial name
- NCT07600814
- Testing
- m-Cresol 0.1%, m-Cresol 0.25%, Control Solution
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Obesity
ZGN-440 (Beloranib for Subcutaneous Injection) for Treatment of Obesity
The purpose of this study is to assess the Pharmacokinetics/Pharmacodynamics (PK/PD), safety, and effectiveness of multiple subcutaneous doses of Beloranib (ZGN-440).
- Trial name
- NCT01507077
- Testing
- ZGN-440, ZGN-440 sterile diluent
- Where
- Australia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Zafgen, Inc.
Healthy Men and Women
Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects
A single-center, open-label, randomized study with a screening period of up to 21 days. Following that, eligible men and women will receive 50 mg of etanercept subcutaneously in the thigh to compare injection by auto-injection…
- Trial name
- NCT02588534
- Testing
- etanercept (ENBREL®) via auto-injector device, Etanercept (ENBREL®) via Manual injection
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Amgen
Prevention of Infection With HIV-1
Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
The is a blinded safety study of ibalizumab given by subcutaneous injection in sequentially increasing dose-groups of at-risk, HIV-negative, healthy volunteers.
- Trial name
- TMB-108 (NCT01292174)
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Injection Site Reaction
A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.
A Phase IV, Randomised, Double-blind, Single-centre clinical trial in healthy male and female participants aged 18 to 55, that was designed to assess and compare the pain intensity at an injection site as well as the duration of…
- Trial name
- NCT03841396
- Testing
- Sodium chloride
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Aspen Global Incorporated
Asthma With Eosinophilic Phenotype
A Study Comparing a Pre-filled Safety Syringe and an Autoinjector for SHR-1703 Injection in Healthy Participants
This is a single-center, randomized, parallel-group, open-label clinical study designed to compare the bioavailability and safety of SHR-1703 Injection administered subcutaneously using a pre-filled safety syringe (PFS) or a…
- Trial name
- NCT07701239
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Primary Immune Thrombocytopenia (ITP)
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
A randomized, double-blind, placebo-controlled design was designed to evaluate the safety and tolerability, pharmacokinetic/pharmacodynamic profile, and immunogenicity of multiple administration of STSA-1301 subcutaneous…
- Trial name
- NCT06929299
- Testing
- STSA-1301 subcutaneous injection
- Where
- 7 sites in China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu BioJeTay Biotechnology Co., Ltd.
Healthy
Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.
To investigate the safety and tolerability of BI 1005273 in healthy male volunteers following intravenous (i.v.) infusion of single rising doses and subcutaneous (s.c.) injection.
- Trial name
- NCT01650155
- Testing
- BI 1005273 s.c., BI 1005273 i.v.
- Where
- Germany
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Study Participants
A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
The purpose of the study is to compare the pharmacokinetics (PK) of bimekizumab when administered subcutaneously (sc) as 1x2 mL versus 2x1 mL, using a bimekizumab-safety syringe presentation or bimekizumab-auto-injector…
- Trial name
- NCT04255862
- Testing
- Bimekizumab
- Where
- Germany
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Essential Hypertension, Healthy Volunteers
Phase 1 Clinical Study of MWX401 Injection in Chinese Healthy Participants and Participants With Mild Hypertension
This is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose phase 1 clinical study, aimed at evaluating the safety, tolerability, PK, PD and immunogenicity of single subcutaneous administration of…
- Trial name
- NCT07803835
- Testing
- MWX401 1, MWX401 2, MWX401 3
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Hypercholesterolemia and Hyperlipidemia
Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers
In order to improve the medication convenience and compliance of patients and facilitates in the long-term control of disease condition, it is planned to reduced the number of injections to one per administration.
- Trial name
- NCT06837077
- Testing
- SHR-1209 single-site subcutaneous injection, SHR-1209 multiple-site subcutaneous injections
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Diabetes Mellitus, Type 2
Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.
This study will use scintigraphy techniques to measure gastric emptying rate of liquid and solid food at baseline and after administration of GSK716155 or placebo.
- Trial name
- NCT00537719
- Testing
- GSK716155
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pharmacokinetics, Safety
Study to Compare PK & Safety of Advixa With Humira in Healthy, Adult Subject Followed by Efficacy & Safety Study in RA Patients
Adalimumab is a recombinant monoclonal antibody (IgG1 subclass) against human TNF-α (Tumor Necrosis Factor-alpha). It is an immunosuppressive medication predominantly used to treat rheumatoid arthritis autoimmune disease.
- Conditions
- Pharmacokinetics, Safety, Efficacy, Rheumatoid Arthritis
- Trial name
- ACT (NCT05172817)
- Testing
- Advixa (Adalimumab)
- Where
- Bangladesh
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute for Developing Science and Health Initiatives, Bangladesh
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Primary Immune Thrombocytopenia
The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects
A randomized, double-blind, placebo-controlled, single-ascending dose, phase Ia study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamics, and immunogenicity of STSA-1301 Subcutaneous Injection in healthy…
- Trial name
- NCT06148389
- Testing
- STSA-1301 subcutaneous injection
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
Type 1 Diabetes
Impact of Insulin Deprivation and Hyperglycemia on Plasma Protein Synthesis in People With Type 1 Diabetes Mellitus
This research is being done to better understand how insulin effects muscle, blood, and the body in people with Type 1 Diabetes.
- Trial name
- NCT05985135
- Testing
- Muscle Biopsy, Jell-O with Amino acids, Dextrose
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mayo Clinic
Nursing Education, Nursing Education Research
The Effect of Using Virtual Reality in Subcutaneous Injection Education on the Knowledge and Skills of Nursing Students
The goal of this clinical trial is to evaluate whether virtual reality (VR)-based education improves nursing students' knowledge and skill levels related to subcutaneous injection.
- Conditions
- Nursing Education, Nursing Education Research, Virtual Goggles, Virtual Reality
- Trial name
- NCT07012187
- Testing
- They will watch a video on subcutaneous injection application using virtual reality technology (virtual reality glasses).
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Baskent University
Nursing Care
The Effect of Nurse Training on the Improvement of Subcutaneous Heparin Applications
One of the most important duties and responsibilities of nurses is drug administration. During drug administration, the nurse uses appropriate administration techniques and ensures patient safety by knowing the drugs and their…
- Trial name
- NCT05469035
- Testing
- Mobile-based video, Face-to-face
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Istanbul Saglik Bilimleri University
Diabetes, Healthy
To Investigate the Blood Concentration of Liraglutide as Well as the Effects on Glucose and Insulin After 21 Days of Daily Subcutaneous Injections of Liraglutide or Placebo
This trial is conducted in Asia. The aim of this clinical trial is to investigate the blood concentration of liraglutide (pharmacokinetics) as well as the effects on glucose and insulin (pharmacodynamics) after 21 days of daily…
- Trial name
- NCT00761540
- Testing
- liraglutide
- Where
- China
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S